# Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease

> **NCT00054613** · PHASE2 · COMPLETED · sponsor: **Mallinckrodt** · enrollment: 72 (—)

## Conditions studied

- Graft-versus-Host Disease

## Interventions

- **DRUG:** Methoxsalen
- **PROCEDURE:** Extracorporeal Photopheresis

## Key facts

- **NCT ID:** NCT00054613
- **Lead sponsor:** Mallinckrodt
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** —
- **Final completion:** 2004-03
- **Target enrollment:** 72 (—)
- **Last updated:** 2017-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00054613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00054613, "Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00054613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*